Carmen Jackson
Family · Waycross, GANPI 1306368329
Payments from drug & device makers
Across 108 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$390
- Astellas Pharma US Inc$216
- E.r. Squibb & Sons, L.L.C.$198
- AbbVie$167
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$162
- Paratek Pharmaceuticals, Inc.$150
- plus $880 from 23 others
What the payments were for
- Food & beverage$2,164100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,164 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $110,628 |
| MounjaroTirzepatide | 77 | $87,300 |
| EliquisApixaban | 61 | $45,437 |
| JanuviaSitagliptin Phosphate | 52 | $39,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $36,698 |
| LinzessLinaclotide | 43 | $31,781 |
| FarxigaDapagliflozin Propanediol | 25 | $24,260 |
| JardianceEmpagliflozin | 16 | $22,013 |
| EntrestoSacubitril/Valsartan | 11 | $20,587 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $18,125 |
| RybelsusSemaglutide | 14 | $17,775 |
| Emgality PenGalcanezumab-Gnlm | 20 | $13,935 |
| MyrbetriqMirabegron | 23 | $13,032 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $9,970 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $390 | $128,403101 claims |
| Lilly USA, LLCMounjaro | $44 | $87,30077 claims |
| PfizerEliquis | $30 | $45,43761 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $70 | $41,57070 claims |
| GSKTrelegy Ellipta | $27 | $36,69841 claims |
| AbbVieLinzess, Synthroid | $167 | $33,74864 claims |
| NovartisEntresto | $21 | $20,58711 claims |
| Astellas Pharma US IncMyrbetriq | $216 | $13,03223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Waycross
- Hannah BanachWaycross$85K
- Tiffany HarkleroadWaycross$16K
- Morgan EldridgeWaycross$15K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Morgan GroothandEvans$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.